Delivery Order SPE2DR25D1021-SPE2DR26FNL3S
- Not listed
- The Defense Logistics Agency awarded a $8,381.10 delivery order to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin on September 25, 2025, with an ultimate completion date of October 17, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The contract does not utilize a set-aside designation and...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,793.70 firm fixed-price delivery order for 100-unit vials of Xeomin on July 11, 2025, with an ultimate completion date of August 1, 2025. The order will be fulfilled at the company's corporate office location in Conshohocken, Pennsylvania. This competitively awarded delivery order carries no set-aside designation and represents a child contract under AmerisourceBergen's larger federal contract portfolio with the DLA. This...
- The Defense Logistics Agency awarded a $46,934.16 delivery order to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin on July 18, 2025, with an ultimate completion date of August 8, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Xeomin 100 Unit Vials, with a ceiling value of $5,989.62 and an ultimate completion date of October 9, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under an open procurement process. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania, where the company serves as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Xeomin 100 unit vials valued at $6,704.88 with a firm fixed price structure. The order is scheduled for completion by August 19, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania location. This delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Xeomin 50 unit vials valued at $10,941.84. This competitively awarded, non-set-aside contract is structured as a firm fixed price delivery order with a completion date of September 10, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order falls under the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,174.80 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin on September 10, 2025, with an ultimate completion date of October 1, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. Xeomin is a botulinum toxin product used primarily for medical and aesthetic applications, and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,676.22 to supply 100-unit vials of Xeomin on July 23, 2025, with an ultimate completion date of August 13, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Xeomin is a botulinum toxin product used for therapeutic and cosmetic medical applications within military...
- AmerisourceBergen Drug Corp was awarded a $5,587.40 delivery order by the Defense Logistics Agency (DLA) on October 23, 2025, for the supply of 100-unit vials of Xeomin. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of November 14, 2025, and represents performance at the vendor's corporate office location in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation, demonstrating AmerisourceBergen's...
- The Defense Logistics Agency awarded a $9,118.20 firm fixed price delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of Xeomin 50 Unit Vials, with an ultimate completion date of July 11, 2025. This non-set-aside contract is a child delivery order executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. The pharmaceutical distributor,...
- SPE2DR25D1021Indefinite Delivery Contract
- SPE2DR25D1021-SPE2DR26FNL3SDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,766.46 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin on October 24, 2025, with an ultimate completion date of November 17, 2025. This is a firm fixed price contract with no set-aside designation, competitively awarded through an open process. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion prime vendor agreement running through December 2026 that supports global pharmaceutical supply to military and veteran healthcare systems. Xeomin, a botulinum toxin product used in medical and aesthetic applications, represents one of the specialized pharmaceutical products the company supplies through its comprehensive federal medical procurement portfolio. AmerisourceBergen's extensive contract history with the DLA demonstrates its established capability as a critical pharmaceutical distributor for federal medical supply chain needs across multiple therapeutic domains, including specialty medications, vaccines, and medical devices.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 10/24/25 |